Thera-SAbDab

BRIAKINUMAB

>   Structural Summary
TherapeuticBriakinumab
TargetIL12B
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS
Light ChainQSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL
100% seqID Fv Structure5n2k%3ALK%3ABA%3APO%3ADC%3ANM%3AFE [Fvs: ]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Preregistration %28w%29
Estimated Status (August '23)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedCambridge Antibody Technology%3BAbbott GmbH %26 Co. KG
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedPlaque psoriasis%3BCrohn%27s disease%3BMultiple sclerosis%3BRheumatoid arthritis
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy